Literature DB >> 33576947

Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.

Caglar Berkel1, Ercan Cacan2.   

Abstract

Ovarian cancer (OC) is the most lethal gynecological malignancy and cellular mechanisms regulating OC progression are not completely understood. miRNAs are involved in many signaling pathways which are critical for the progression of malignant tumors, including OC. In the present study, we aim to identify miRNAs whose expression change in a tumor stage- and/or grade-dependent manner in serous OC. Computational analysis was performed in R using The Cancer Genome Atlas miRNA dataset. Kaplan-Meier plots were constructed to compare the survival of patients with low and high expressions of identified miRNAs. We found that 91 and 90 miRNAs out of 799 are differentially expressed in terms of tumor stage and grade, respectively. miR-152, miR-375 and miR-204 were top three hits in terms of tumor stage; and similarly, miR-125b, miR-768-5p and -3p in terms of tumor grade. Among top 15 miRNAs whose expression most significantly changed between tumor stages, 66.7% were upregulated in late stage. However, 53.3% of top 15 miRNAs identified in terms of tumor grade were upregulated in high grade. 11 miRNAs are differentially expressed in terms of both tumor stage and grade. Expression changes of some of the top miRNAs were found to be associated with shorter survival in serous OC. Text mining analysis showed that most of these miRNAs have not been previously studied in the context of OC. Mechanistic studies of these miRNAs in OC progression, differentiation and metastasis will be of high importance to develop novel strategies for the treatment of serous ovarian cancer.

Entities:  

Keywords:  Cancer progression; Serous ovarian cancer; Transcriptomics; Tumor grade; Tumor stage; miRNA

Year:  2021        PMID: 33576947     DOI: 10.1007/s13577-021-00486-3

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  34 in total

Review 1.  Regulation of microRNA biogenesis.

Authors:  Minju Ha; V Narry Kim
Journal:  Nat Rev Mol Cell Biol       Date:  2014-07-16       Impact factor: 94.444

Review 2.  miRNAs and ovarian cancer: An overview.

Authors:  Bornali Deb; Arif Uddin; Supriyo Chakraborty
Journal:  J Cell Physiol       Date:  2017-08-25       Impact factor: 6.384

Review 3.  The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer.

Authors:  Hamideh Aboutalebi; Afsane Bahrami; Atena Soleimani; Nikoo Saeedi; Farzad Rahmani; Majid Khazaei; Hamid Fiuji; Mojtaba Shafiee; Gordon A Ferns; Amir Avan; Seyed Mahdi Hassanian
Journal:  Int J Biochem Cell Biol       Date:  2020-05-17       Impact factor: 5.085

4.  GAB2 and GAB3 are expressed in a tumor stage-, grade- and histotype-dependent manner and are associated with shorter progression-free survival in ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  J Cell Commun Signal       Date:  2020-09-04       Impact factor: 5.782

5.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

Review 6.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

7.  Pairing beyond the Seed Supports MicroRNA Targeting Specificity.

Authors:  James P Broughton; Michael T Lovci; Jessica L Huang; Gene W Yeo; Amy E Pasquinelli
Journal:  Mol Cell       Date:  2016-10-06       Impact factor: 17.970

8.  In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Cell Biol Int       Date:  2020-03-24       Impact factor: 3.612

Review 9.  Ovarian cancer standard of care: are there real alternatives?

Authors:  Chiara Della Pepa; Giuseppe Tonini; Carmela Pisano; Marilena Di Napoli; Sabrina Chiara Cecere; Rosa Tambaro; Gaetano Facchini; Sando Pignata
Journal:  Chin J Cancer       Date:  2015-01

Review 10.  Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.

Authors:  Abhineet Uppal; Mark K Ferguson; Mitchell C Posner; Samuel Hellman; Nikolai N Khodarev; Ralph R Weichselbaum
Journal:  Clin Exp Metastasis       Date:  2014-06-27       Impact factor: 5.150

View more
  3 in total

1.  Lower expression of NINJ1 (Ninjurin 1), a mediator of plasma membrane rupture, is associated with advanced disease and worse prognosis in serous ovarian cancer.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Immunol Res       Date:  2022-10-03       Impact factor: 4.505

2.  Sex-specific changes in the expression of ER-alpha and androgen receptor with increasing tumor grade in patients with hepatocellular carcinoma.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Hum Cell       Date:  2022-03-29       Impact factor: 4.374

3.  Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Inflammation       Date:  2021-06-06       Impact factor: 4.092

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.